[Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer].
We retrospectively reviewed pretreatment levels of serum prostate specific antigen (PSA) in 138 newly diagnosed, untreated patients with prostate adenocarcinoma to evaluate the usefulness of serum PSA levels to predict results of radionuclide bone scans. All of the 24 patients with serum PSA levels above 200 ng/ml showed positive bone scans whereas those with serum PSA levels below 10 ng/ml included only three cases (3/51, 5.1%) positive for bone metastasis. All of the three had poorly differentiated adenocarcinoma of the prostate. In conclusion, bone scans may not be necessary in the cases with serum PSA levels less than 10 ng/ml except for those with poorly differentiated adenocarcinoma.
Kageyama
Y
Y
Department of Urology, Tokyo Medical and Dental University School of Medicine, Japan.
Kihara
K
K
Kamata
S
S
Nagahama
K
K
Yonese
J
J
Fukuda
H
H
Tosaka
A
A
Nagamatsu
H
H
Ishizaka
K
K
Tsujii
T
T
Kitahara
S
S
Morita
T
T
Oshima
H
H
D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000276:immunology / Q000556:secondary; D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000276:immunology / Q000556:secondary*; D001842:Bone and Bones / Q000000981:diagnostic imaging; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000473:pathology; D011877:Radionuclide Imaging; D012189:Retrospective Studies
D017430:Prostate-Specific Antigen